Particularly encouraging is Matthew Schissler’s career trajectory, which paints a picture of an entrepreneur who has patiently and precisely adjusted to changing business environments over time. He is a living example of deliberate reinvention, with an estimated net worth of $2.68 million in 2025. His professional background, which includes biotechnology and private equity, demonstrates a remarkable grasp of how businesses change and where value is found in the future.
Schissler was born on June 9, 1971, and quickly made a name for himself as a creative leader. His establishment of Cord Blood America, Inc. (CBAI) was a turning point in biotechnology, particularly at a time when stem cell research was becoming more popular but needed a business foundation. His business allowed families to invest in possible medical futures by extracting and keeping umbilical cord stem cells. The idea was remarkably progressive; it combined compassion and science, appealing to expectant parents who wanted to maintain hope in biological form.
| Personal & Professional Information | Details |
|---|---|
| Full Name | Matthew Schissler |
| Date of Birth | June 9, 1971 |
| Age (as of 2025) | 54 years |
| Nationality | American |
| Occupation | Entrepreneur, Private Investor |
| Known For | Founder of Cord Blood America, Inc. |
| Current Role | Managing Member, GHS Investments & Work Your Core Investments |
| Estimated Net Worth (2025) | $2.68 Million |
| Investment Focus | Growth-stage and undervalued small-to-mid cap companies |
| Affiliations | Aztec Airways, Nevada Development Authority, Karma Foundation |
| Award Recognition | Ernst & Young Entrepreneur of the Year Finalist (2008) |
| Residence | United States |
| Reference |
By spearheading CBAI, Schissler showed how a single concept, based on research but motivated by financial acumen, might change how people think about healthcare innovation. His leadership style was particularly pragmatic; he placed a strong emphasis on legitimacy, public awareness, and steady growth in an industry that is frequently condemned for speculating. Under his direction, Cord Blood America grew both domestically and abroad, demonstrating the company’s commercial feasibility and the confidence of its customers in stem cell preservation.
Schissler’s transition from biotechnology to investment management over time was a reflection of his exceptionally good ability to spot trends before they became established. He has been managing private investment funds since 2015, concentrating on small and mid-cap firms that are undervalued. His approach is based on careful research rather than conjecture; he looks for businesses with solid foundations that conventional markets might miss. He has been able to seize growth where others perceived uncertainty thanks to this “super value” concept, which has been especially helpful during uncertain economic times.
As the founder and managing member of GHS Investments, LLC, Schissler uses his background to help companies in the consumer, healthcare, and technology sectors who are focused on expansion. He frequently characterizes investing as “an act of foresight guided by patience,” a phrase that perfectly captures his methodical style. Through these endeavors, he has established a reputation as an investor who is both numerate and narratively savvy, understanding that a company’s ability to tell its story is frequently just as important to its long-term success as its performance.
He continued to be curious about entrepreneurship. Schissler established the fitness and wellness franchise-focused fund Work Your Core Investments (WYC), LLC in 2021. This action was taken at a critical juncture when the global wellness markets were growing quickly. His emphasis on franchise ownership and performance-based fitness was especially creative, capitalizing on societal shifts toward experiential consumption and better lifestyles. The tactic established WYC as a very effective means of capitalizing on long-term cultural changes as opposed to passing trends.
Schissler joined Aztec Airways’ Board of Directors that same year. Aztec Airways is a Florida-based airline that has FAA Part 135 certification. His interest in aviation is indicative of a larger investment philosophy that looks for opportunities in sectors that have the potential for modernization and consistent demand. His position at Aztec Airways demonstrates his readiness to carefully diversify while continuing to monitor risk and return.
Schissler’s influence goes beyond business endeavors motivated by profit. His involvement with the Las Vegas Science Festival and Natural History Museum, as well as his membership on the Nevada Development Authority’s Biotech Committee, demonstrate his dedication to community involvement. He sees science and education as the two cornerstones of progress and frequently promotes cooperation between public educational institutions and commercial industry. This philosophy is further supported by his affiliation with the Karma Foundation, which links him to charitable endeavors that place a high value on social awareness, education, and health.
Schissler’s accomplishments were acknowledged in 2008 when he was selected as a finalist for the Ernst & Young Entrepreneur of the Year Award. The recognition demonstrated his wide-ranging impact, not only as a businessman but also as a strategist who could turn abstract concepts into real achievements. It was a turning point that confirmed years of perseverance, especially when skepticism and invention were incompatible.
Schissler’s $2.68 million net worth now signifies more than just amassed money; it also marks decades of flexibility and wise risk-taking. His strategy is deliberate and long-term, in contrast to entrepreneurs who strive for quick development. He believes that economic advantages should follow societal growth, thus he invests where progress meets purpose. His work, particularly in the areas of fitness investment and stem cell preservation, demonstrates a faith in sectors that enhance people’s health and well-being — a strikingly successful fusion of business and ethics.
The transition from operational leadership to strategic investment is an increasing trend among contemporary entrepreneurs, and Schissler’s development reflects this trend in the larger corporate environment. Many entrepreneurs who have spent years creating and managing businesses now focus on fostering others by providing not only funding but also guidance, organization, and vision. This transformation is aptly exemplified by Schissler’s journey from biotech pioneer to investing leader, which uniquely and persistently connects experience and innovation.
For aspiring business owners, his experience also serves as a crucial reminder that success is rarely linear. What distinguishes those who persist from those who fade is the capacity to change course, to discern when one chapter has fulfilled its function. Schissler demonstrates how long-term success is dependent on ongoing inquiry and strategic evolution rather than on isolated accomplishments through his methodical diversification and foresight.
